Navigation Links
King's College London reveals promising techniques for extending the life of an organ transplant
Date:9/15/2010

Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life.

Although organ transplantation has been taking place for over 50 years, there are a number of significant challenges, such as a shortage of donor organs, maintaining the quality of an organ in transit, and the risk of organ rejection both immediately after transplant and in the following years.

Scientists at King's College London, part of King's Health Partners Academic Health Sciences Centre, are working hard to solve these problems through techniques known as protein therapeutics and cell therapy.

Protein therapeutics

The work using protein therapeutics aims to reduce the risk of an organ being damaged in the hours and days following a transplant, by maintaining the quality of the donor organ prior to transplantation.

Currently, organs cannot survive outside the body for more than around 24 hours. In daily life when an infection or virus meets cells or fluids in the body, it activates a part of the immune system, known as the 'complement' system, which attacks and attempts to destroy the cells of the intruder organism.

The complement system is usually kept in check by 'regulators' which are found on the surface of the cells. Their presence prevents it from attacking the body's own cells. However, when an organ is removed for transplantation, complement regulators are lost from the surface of cells due to the lack of blood flow and consequent lack of oxygen. Unregulated, the complement system begins to attack the organ's own cells, severely damaging it. Once the transplant is complete, the effect can be amplified as the complement system supports the recipient's own blood cells in its attack on the organ resul
'/>"/>

Contact: Melanie Haberstroh
melanie.haberstroh@kcl.ac.uk
44-020-784-83076
King's College London
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications
2. TFAH Praises New County Health Rankings Report
3. GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance
4. New Aspen Dental Office to Open in Kingston, New York
5. Jusuru Tops New Company Launch Rankings
6. St. Croix Systems Achieves Record First Half Bookings and Revenues in 2010, Driven by Demand for Innovative Patient Support Services Applications
7. Inner Workings of Gene Tied to Breast, Ovarian Cancer Revealed
8. College Age Females Can Kiss Chlamydia Goodbye for Valentines Day
9. Majority of Americans Approve of President Obamas Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television
10. Parents Divorce Doesnt Harm College-Age Kids
11. Jefferson surgeon receives outstanding performance award from American College Of Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 The deadline to ... this Friday, June 21 at midnight ET. This ... and innovative people who’ve raised the bar on ... http://www.minonline.com/ima . , Any consumer and b2b ... is eligible to enter. Additionally, advertising agencies and ...
(Date:6/19/2013)... Lake City, UT (PRWEB) June 19, 2013 ... companies : , In July 2013, Orriant is ... their participation rates, and maintain compliance with regulations. ... allowing employees to receive wellness incentives if their ... has announced they have been compliant with these ...
(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... international study led by researchers at The University of ... continues to show remarkable promise for the treatment of ... most recent interim findings of the 18-center Phase 2 ... Journal of Medicine . Previous interim findings were presented ... Hematology Annual Meeting and Exposition. , Unprecedented ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Skin Care – How to treat Sunburn 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... alert in India's northeast asking authorities to take ... outbreak in Bangladesh and Myanmar, officials said ... Tripura government has made arrangements for free consultation ... sub-divisions, especially those along the bordering areas," Tripura's ...
... known as a poison that can kill, arsenic also can ... leukemia , a new study out Saturday found. ... we give (arsenic) earlier in the course of treatment," said ... in North Carolina, and the lead author of the research ...
... issue of JAMA, has identified novel genetic mutations linked ... these mutations are due to both independent mutational events ... to coincide with its presentation at the annual meeting ... ,According to background information in the article, gastric cancer ...
... CHICAGO, According to a University of Pittsburgh Medical Center ... American Society of Clinical Oncology (ASCO) in Chicago and ... patients treated for follicular lymphoma, a slow-growing type of ... ,Over 90 percent of study patients responded ...
... CEGE) today announced follow-up data from a Phase 2 ... was conducted by the Johns Hopkins Sidney Kimmel Cancer ... pancreatic cancer who received GVAX after surgical resection of ... overall survival for these patients was previously reported to ...
... receiving end, even if it is all subtle, as in ... to pin down is more dangerous to mental health ... immigrants living in Canada. ,"We found that the ... distress such as symptoms of depression and anxiety," said lead ...
Cached Medicine News:Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 2Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 3Health News:Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... ARBOR, Mich., Nov. 11, 2011 Adeona ... developer of innovative medicines for serious central nervous system ... estriol), will be utilized in a new Phase II ... cognitive dysfunction observed in female multiple sclerosis (MS) patients. ...
... 11, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Officer, will be presenting at the Lazard Capital Markets 8th ... New York City. Mr. Bentsur,s presentation is scheduled to take ... A live audio webcast of Mr. Bentsur,s presentation ...
Cached Medicine Technology:Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 2Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 3Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 4Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 5Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: